Leerink Partnrs Comments on Edwards Lifesciences Co.’s Q1 2025 Earnings (NYSE:EW)

Edwards Lifesciences Co. (NYSE:EW) – Equities research analysts at Leerink Partnrs lowered their Q1 2025 earnings per share estimates for Edwards Lifesciences in a report released on Wednesday, April 17th. Leerink Partnrs analyst M. Kratky now anticipates that the medical research company will earn $0.74 per share for the quarter, down from their prior estimate of $0.75. The consensus estimate for Edwards Lifesciences’ current full-year earnings is $2.76 per share. Leerink Partnrs also issued estimates for Edwards Lifesciences’ Q2 2025 earnings at $0.78 EPS, Q3 2025 earnings at $0.79 EPS and Q4 2025 earnings at $0.80 EPS.

A number of other analysts also recently weighed in on EW. Stifel Nicolaus increased their price target on shares of Edwards Lifesciences from $70.00 to $83.00 and gave the company a “hold” rating in a report on Wednesday, February 7th. OTR Global upgraded shares of Edwards Lifesciences from a “mixed” rating to a “positive” rating in a research report on Tuesday, March 26th. Mizuho raised their target price on Edwards Lifesciences from $95.00 to $105.00 and gave the company a “buy” rating in a research note on Thursday, April 11th. Oppenheimer upped their price objective on Edwards Lifesciences from $93.00 to $100.00 and gave the stock an “outperform” rating in a report on Monday, March 18th. Finally, Royal Bank of Canada boosted their price target on shares of Edwards Lifesciences from $95.00 to $101.00 and gave the stock an “outperform” rating in a research note on Monday. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and ten have given a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $91.73.

Edwards Lifesciences Trading Down 0.9 %

Edwards Lifesciences stock opened at $86.45 on Thursday. The business’s 50-day simple moving average is $90.14 and its 200-day simple moving average is $78.19. Edwards Lifesciences has a 52 week low of $60.57 and a 52 week high of $96.12. The firm has a market capitalization of $52.04 billion, a PE ratio of 37.59, a PEG ratio of 4.46 and a beta of 1.05. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.40 and a current ratio of 3.38.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Tuesday, February 6th. The medical research company reported $0.64 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.64. The company had revenue of $1.53 billion during the quarter, compared to the consensus estimate of $1.50 billion. Edwards Lifesciences had a return on equity of 23.56% and a net margin of 23.35%. The firm’s revenue was up 13.3% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.64 EPS.

Insider Activity at Edwards Lifesciences

In related news, CFO Scott B. Ullem sold 7,255 shares of the stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $78.29, for a total transaction of $567,993.95. Following the sale, the chief financial officer now owns 19,248 shares in the company, valued at approximately $1,506,925.92. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Edwards Lifesciences news, CFO Scott B. Ullem sold 7,255 shares of Edwards Lifesciences stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $78.29, for a total value of $567,993.95. Following the transaction, the chief financial officer now owns 19,248 shares in the company, valued at $1,506,925.92. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Heisz Leslie Stone sold 7,056 shares of the firm’s stock in a transaction that occurred on Thursday, February 8th. The shares were sold at an average price of $86.45, for a total transaction of $609,991.20. Following the completion of the sale, the director now owns 26,980 shares in the company, valued at $2,332,421. The disclosure for this sale can be found here. In the last ninety days, insiders sold 194,004 shares of company stock worth $17,166,254. Insiders own 1.29% of the company’s stock.

Institutional Investors Weigh In On Edwards Lifesciences

A number of institutional investors have recently added to or reduced their stakes in the business. Castleview Partners LLC acquired a new position in Edwards Lifesciences in the first quarter valued at approximately $25,000. DSM Capital Partners LLC acquired a new stake in Edwards Lifesciences in the fourth quarter valued at approximately $28,000. Compass Wealth Management LLC acquired a new position in Edwards Lifesciences during the 4th quarter valued at about $31,000. Turtle Creek Wealth Advisors LLC bought a new stake in Edwards Lifesciences during the fourth quarter worth $34,000. Finally, Riverview Trust Co purchased a new stake in Edwards Lifesciences in the 1st quarter valued at $34,000. 79.46% of the stock is owned by institutional investors.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.